Successful Drug Development Despite Adverse Preclinical Findings Part 1: Processes to Address Issues and Most Important Findings

Unexpected adverse preclinical findings (APFs) are not infrequently encountered during drug development. Such APFs can be functional disturbances such as QT prolongation, morphological toxicity or carcinogenicity. The latter is of particular concern in conjunction with equivocal genotoxicity results...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettlin, Robert A., Kuroda, Junji, Plassmann, Stephanie, Prentice, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Toxicologic Pathology 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234634/
https://www.ncbi.nlm.nih.gov/pubmed/22272031
http://dx.doi.org/10.1293/tox.23.189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234634/
https://www.ncbi.nlm.nih.gov/pubmed/22272031
http://dx.doi.org/10.1293/tox.23.189

Ejemplares similares